ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
November 30, 2023 08:00 ET
|
Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
September 07, 2023 17:00 ET
|
Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
June 20, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief...
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond
May 04, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology...
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
January 05, 2023 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022
September 12, 2022 09:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of...
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
May 12, 2022 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM...
Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors
April 26, 2022 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, April 26, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc., the RNA technology company advancing programmable medicine, today announced the addition of two new members to its board of...
Shape Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 06, 2022 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company creating the future of RNA technologies, today announced that Francois Vigneault, PhD.,...
Shape Therapeutics Appoints David J. Huss, Ph.D., as Chief Scientific Officer and Lisa Taylor Ash, J.D., as General Counsel
November 09, 2021 08:00 ET
|
Shape Therapeutics, Inc.
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment...